Literature DB >> 15071384

Costs associated with delirium in mechanically ventilated patients.

Eric B Milbrandt1, Stephen Deppen, Patricia L Harrison, Ayumi K Shintani, Theodore Speroff, Renée A Stiles, Brenda Truman, Gordon R Bernard, Robert S Dittus, E Wesley Ely.   

Abstract

OBJECTIVE: To determine the costs associated with delirium in mechanically ventilated medical intensive care unit patients.
DESIGN: Prospective cohort study.
SETTING: A tertiary care academic hospital. PATIENTS: Patients were 275 consecutive mechanically ventilated medical intensive care unit patients.
INTERVENTIONS: We prospectively examined patients for delirium using the Confusion Assessment Method for the Intensive Care Unit.
MEASUREMENTS AND MAIN RESULTS: Delirium was categorized as "ever vs. never" and by a cumulative delirium severity index. Costs were determined from individual ledger-level patient charges using cost-center-specific cost-to-charge ratios and were reported in year 2001 U.S. dollars. Fifty-one of 275 patients (18.5%) had persistent coma and died in the hospital and were excluded from further analysis. Of the remaining 224 patients, delirium developed in 183 (81.7%) and lasted a median of 2.1 (interquartile range, 1-3) days. Baseline demographics were similar between those with and without delirium. Intensive care unit costs (median, interquartile range) were significantly higher for those with at least one episode of delirium ($22,346, $15,083-$35,521) vs. those with no delirium ($13,332, $8,837-$21,471, p <.001). Total hospital costs were also higher in those who developed delirium ($41,836, $22,782-$68,134 vs. $27,106, $13,875-$37,419, p =.002). Higher severity and duration of delirium were associated with incrementally greater costs (all p <.001). After adjustment for age, comorbidity, severity of illness, degree of organ dysfunction, nosocomial infection, hospital mortality, and other potential confounders, delirium was associated with 39% higher intensive care unit (95% confidence interval, 12-72%) and 31% higher hospital (95% confidence interval, 1-70%) costs.
CONCLUSIONS: Delirium is a common clinical event in mechanically ventilated medical intensive care unit patients and is associated with significantly higher intensive care unit and hospital costs. Future efforts to prevent or treat intensive care unit delirium have the potential to improve patient outcomes and reduce costs of care.

Entities:  

Mesh:

Year:  2004        PMID: 15071384     DOI: 10.1097/01.ccm.0000119429.16055.92

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  228 in total

1.  Postoperative delirium: a 76-year-old woman with delirium following surgery.

Authors:  Edward R Marcantonio
Journal:  JAMA       Date:  2012-07-04       Impact factor: 56.272

2.  The Confusion Assessment Method for the ICU-7 Delirium Severity Scale: A Novel Delirium Severity Instrument for Use in the ICU.

Authors:  Babar A Khan; Anthony J Perkins; Sujuan Gao; Siu L Hui; Noll L Campbell; Mark O Farber; Linda L Chlan; Malaz A Boustani
Journal:  Crit Care Med       Date:  2017-05       Impact factor: 7.598

3.  Enhancing care for hospitalized older adults with cognitive impairment: a randomized controlled trial.

Authors:  Malaz A Boustani; Noll L Campbell; Babar A Khan; Greg Abernathy; Mohammed Zawahiri; Tiffany Campbell; Jason Tricker; Siu L Hui; John D Buckley; Anthony J Perkins; Mark O Farber; Christopher M Callahan
Journal:  J Gen Intern Med       Date:  2012-05       Impact factor: 5.128

4.  Comparison and agreement between the Richmond Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in evaluating patients' eligibility for delirium assessment in the ICU.

Authors:  Babar A Khan; Oscar Guzman; Noll L Campbell; Todd Walroth; Jason L Tricker; Siu L Hui; Anthony Perkins; Mohammed Zawahiri; John D Buckley; Mark O Farber; E Wesley Ely; Malaz A Boustani
Journal:  Chest       Date:  2012-07       Impact factor: 9.410

Review 5.  Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research--a systematic evidence review.

Authors:  Babar A Khan; Mohammed Zawahiri; Noll L Campbell; George C Fox; Eric J Weinstein; Arif Nazir; Mark O Farber; John D Buckley; Alasdair Maclullich; Malaz A Boustani
Journal:  J Hosp Med       Date:  2012-06-08       Impact factor: 2.960

6.  The assessment and management of agitation and delirium in the general hospital.

Authors:  Theodore A Stern; Christopher M Celano; Anne F Gross; Jeff C Huffman; Oliver Freudenreich; Nicholas Kontos; Shamim H Nejad; Jennifer Repper-Delisi; B Taylor Thompson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

7.  Corticosteroids and transition to delirium in patients with acute lung injury.

Authors:  Matthew P Schreiber; Elizabeth Colantuoni; Oscar J Bienvenu; Karin J Neufeld; Kuan-Fu Chen; Carl Shanholtz; Pedro A Mendez-Tellez; Dale M Needham
Journal:  Crit Care Med       Date:  2014-06       Impact factor: 7.598

8.  Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals.

Authors:  Rina P Patel; Meredith Gambrell; Theodore Speroff; Theresa A Scott; Brenda T Pun; Joyce Okahashi; Cayce Strength; Pratik Pandharipande; Timothy D Girard; Hayley Burgess; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

9.  Neurological examination of critically ill patients: a pragmatic approach. Report of an ESICM expert panel.

Authors:  Tarek Sharshar; Giuseppe Citerio; Peter J D Andrews; Arturo Chieregato; Nicola Latronico; David K Menon; Louis Puybasset; Claudio Sandroni; Robert D Stevens
Journal:  Intensive Care Med       Date:  2014-02-13       Impact factor: 17.440

10.  Intensive care unit environment may affect the course of delirium.

Authors:  Irene J Zaal; Carolina F Spruyt; Linda M Peelen; Maarten M J van Eijk; Rens Wientjes; Margriet M E Schneider; Jozef Kesecioglu; Arjen J C Slooter
Journal:  Intensive Care Med       Date:  2012-10-24       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.